Protalix Achieves Key Milestones and Remains Debt-Free

Protalix ( (PLX) ) has issued an update.

Protalix BioTherapeutics announced significant achievements in 2024, including the validation of Chiesi’s submission for a less frequent dosing regimen of pegunigalsidase alfa for Fabry disease patients in the EU. The company completed a phase I trial for PRX 115, showing promise for treating gout, and is debt-free after repaying all convertible notes. Despite the challenges of regional conflicts in Israel, Protalix has maintained uninterrupted operations, positioning itself for future growth and innovation.

More about Protalix

Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing recombinant therapeutic proteins through its proprietary plant cell-based expression system, ProCellEx. It was the first to gain FDA approval for a protein produced via plant cell-based suspension expression, and it has partnerships with Pfizer and Chiesi Farmaceutici for the development and commercialization of its products.

YTD Price Performance: -1.12%

Average Trading Volume: 316,954

Technical Sentiment Consensus Rating: Sell

Current Market Cap: $129.6M

See more insights into PLX stock on TipRanks’ Stock Analysis page.